GI
ANAB icon

Gradient Investments’s AnaptysBio ANAB Stock Holding History

Gradient Investments’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23
Closed -$493 – 1262
2023
Q4 		$493 Hold
23
– – ﹤0.01% 1596
2023
Q3 		$413 Hold
23
– – ﹤0.01% 1584
2023
Q2 		$468 Buy
+23
New +$466 ﹤0.01% 1544

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Gradient Investments's ANAB Position: Q1 2024 in Review

Gradient Investments sold out of AnaptysBio (ANAB) in Q1 2024, closing a stake of 23 shares — an estimated $493 sold.

Gradient Investments first reported a position in ANAB in Q2 2023 and held it in 3 quarters. The position peaked at $493 in Q4 2023. 133 funds tracked by Wall St. Rank hold ANAB as of Q1 2024.

  • Gradient Investments reported no remaining AnaptysBio position as of Q1 2024 after selling out during the quarter.
  • Gradient Investments sold 23 AnaptysBio shares in Q1 2024, an estimated $493.
  • Gradient Investments first reported a position in AnaptysBio in Q2 2023 and held it in 3 quarters.
  • Gradient Investments's AnaptysBio position peaked at $493 in Q4 2023.
  • 133 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2024.

Based on Gradient Investments's 13F filing for Q1 2024, filed 23 Apr 2024.